Literature DB >> 33363544

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.

Hongbo Zhang1, Xuesong Li2, Yuntao Li1, Baodong Chen3, Zhitao Zong4, Liang Shen5.   

Abstract

Background: Lower-grade gliomas (LGGs) have more favorable outcomes than glioblastomas; however, LGGs often progress to process glioblastomas within a few years. Numerous studies have proven that the tumor microenvironment (TME) is correlated with the prognosis of glioma.
Methods: LGG RNA-Sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) were extracted and then divided into training and testing cohorts, respectively. Immune-related differentially expressed genes (DEGs) were screened to establish a prognostic signature by a multivariate Cox proportional hazards regression model. The immune-related risk score and clinical information, such as age, sex, World Health Organization (WHO) grade, and isocitrate dehydrogenase 1 (IDH1) mutation, were used to independently validate and develop a prognostic nomogram. GO and KEGG pathway analyses to DEGs between immune-related high-risk and low-risk groups were performed.
Results: Sixteen immune-related genes were screened for establishing a prognostic signature. The risk score had a negative correlation with prognosis, with an area under the receiver operating characteristic (ROC) curve of 0.941. The risk score, age, grade, and IDH1 mutation were identified as independent prognostic factors in patients with LGGs. The hazard ratios (HRs) of the high-risk score were 5.247 [95% confidence interval (CI) = 3.060-8.996] in the multivariate analysis. A prognostic nomogram of 1-, 3-, and 5-year survival was established and validated internally and externally. Go and KEGG pathway analyses implied that immune-related biological function and pathways were involved in the TME.
Conclusion: The immune-related prognostic signature and the prognostic nomogram could accurately predict survival.
Copyright © 2020 Zhang, Li, Li, Chen, Zong and Shen.

Entities:  

Keywords:  glioma; immune; lower-grade gliomas; prognostic signature; risk score

Mesh:

Substances:

Year:  2020        PMID: 33363544      PMCID: PMC7753319          DOI: 10.3389/fimmu.2020.603341

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  44 in total

1.  IDH1 and IDH2 mutations in gliomas.

Authors:  François Ducray; Yannick Marie; Marc Sanson
Journal:  N Engl J Med       Date:  2009-05-21       Impact factor: 91.245

2.  L1 penalized estimation in the Cox proportional hazards model.

Authors:  Jelle J Goeman
Journal:  Biom J       Date:  2010-02       Impact factor: 2.207

Review 3.  Glioma infiltration and extracellular matrix: key players and modulators.

Authors:  Valéria Pereira Ferrer; Vivaldo Moura Neto; Rolf Mentlein
Journal:  Glia       Date:  2018-02-21       Impact factor: 7.452

4.  An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme.

Authors:  Meng Zhou; Zhaoyue Zhang; Hengqiang Zhao; Siqi Bao; Liang Cheng; Jie Sun
Journal:  Mol Neurobiol       Date:  2017-05-19       Impact factor: 5.590

5.  Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients.

Authors:  Sharon A Oldford; J Desmond Robb; Dianne Codner; Veeresh Gadag; Peter H Watson; Sheila Drover
Journal:  Int Immunol       Date:  2006-09-20       Impact factor: 4.823

6.  A 4-gene panel predicting the survival of patients with glioblastoma.

Authors:  Xiao-Xia Guo; Jiao Su; Xiao-Feng He
Journal:  J Cell Biochem       Date:  2019-05-13       Impact factor: 4.429

7.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Authors:  Nikhil Wagle; Caroline Emery; Michael F Berger; Matthew J Davis; Allison Sawyer; Panisa Pochanard; Sarah M Kehoe; Cory M Johannessen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Levi A Garraway
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

Review 8.  Emerging treatment strategies for glioblastoma multiforme.

Authors:  Steven K Carlsson; Shaun P Brothers; Claes Wahlestedt
Journal:  EMBO Mol Med       Date:  2014-11       Impact factor: 12.137

Review 9.  Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response.

Authors:  Carolyn Shembrey; Nicholas D Huntington; Frédéric Hollande
Journal:  Cancers (Basel)       Date:  2019-08-21       Impact factor: 6.639

10.  A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy.

Authors:  Jingjing Duan; Yongwei Xie; Lijuan Qu; Lingxiong Wang; Shunkai Zhou; Yu Wang; Zhongyi Fan; Shengsheng Yang; Shunchang Jiao
Journal:  J Immunother Cancer       Date:  2018-10-03       Impact factor: 13.751

View more
  7 in total

1.  Glioma Subtypes Based on the Activity Changes of Immunologic and Hallmark Gene Sets in Cancer.

Authors:  Sihan Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-13       Impact factor: 6.055

2.  Identification and Validation of a Gene Signature for Lower-Grade Gliomas Based on Pyroptosis-Related Genes to Predict Survival and Response to Immune Checkpoint Inhibitors.

Authors:  Guichuan Lai; Kangjie Li; Jielian Deng; Hui Liu; Biao Xie; Xiaoni Zhong
Journal:  J Healthc Eng       Date:  2022-04-30       Impact factor: 3.822

3.  A Novel CRISPR/Cas9 Screening Potential Index for Prognostic and Immunological Prediction in Low-Grade Glioma.

Authors:  Xiangpan Li; Kewei Xiong; Dong Bi; Chen Zhao
Journal:  Front Genet       Date:  2022-04-25       Impact factor: 4.772

4.  Construction and Verification of a Glycolysis-Associated Gene Signature for the Prediction of Overall Survival in Low Grade Glioma.

Authors:  Wei Liu; Chunshan Liu; Chengcong Chen; Xiaoting Huang; Qi Yi; Yunhong Tian; Biao Peng; Yawei Yuan
Journal:  Front Genet       Date:  2022-03-23       Impact factor: 4.599

5.  APOLLO: An accurate and independently validated prediction model of lower-grade gliomas overall survival and a comparative study of model performance.

Authors:  Jiajin Chen; Sipeng Shen; Yi Li; Juanjuan Fan; Shiyu Xiong; Jingtong Xu; Chenxu Zhu; Lijuan Lin; Xuesi Dong; Weiwei Duan; Yang Zhao; Xu Qian; Zhonghua Liu; Yongyue Wei; David C Christiani; Ruyang Zhang; Feng Chen
Journal:  EBioMedicine       Date:  2022-04-15       Impact factor: 11.205

6.  P-Rex1 Signaling Hub in Lower Grade Glioma Patients, Found by In Silico Data Mining, Correlates With Reduced Survival and Augmented Immune Tumor Microenvironment.

Authors:  Yarely Mabell Beltrán-Navarro; Guadalupe Reyes-Cruz; José Vázquez-Prado
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

7.  Association of glioma CD44 expression with glial dynamics in the tumour microenvironment and patient prognosis.

Authors:  Zhanxin Du; Yaqing Wang; Jiaqi Liang; Shaowei Gao; Xiaoying Cai; Yu Yu; Zhihui Qi; Jing Li; Yubin Xie; Zhongxing Wang
Journal:  Comput Struct Biotechnol J       Date:  2022-09-09       Impact factor: 6.155

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.